Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate
31/08/2026 11:16
BRIEF-Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate Aug 31 (Reuters) - Cipla Ltd CIPL.NS:
CO AND SBP GROUP SIGN EXCLUSIVE LICENSING AGREEMENT FOR HER2 BISPECIFIC ADC TQB2102
RECEIVES EXCLUSIVE RIGHTS TO DEVELOP TQB2102 IN INDIA, SOUTH AFRICA AND 5 MARKETS
Source text: ID:nBSE68xVd
Further company coverage: CIPL.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate